RxDoctor Payments Data

Stacy Marriott, APRN

Family · Alton, ILNPI 1255981528

Payments from drug & device makers

$1,203in general payments, 2019–2025

Across 52 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$286
  • AbbVie$269
  • Lilly USA, LLC$116
  • Amgen$105
  • Boehringer Ingelheim$77
  • Coloplast$75
  • plus $275 from 10 others

What the payments were for

  • Food & beverage$1,18599%
  • Other$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,203 in reported general payments places this provider in the 75th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$2,614
Medicare patients
111
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$95,662
MounjaroTirzepatide48$73,819
JardianceEmpagliflozin35$41,190
FarxigaDapagliflozin Propanediol41$36,311
WegovySemaglutide16$23,242
XareltoRivaroxaban16$19,077
LinzessLinaclotide11$14,258
TrulicityDulaglutide11$12,445
EliquisApixaban11$9,903
Pitavastatin Calcium12$5,729
VascepaIcosapent Ethyl12$3,062
SynthroidLevothyroxine Sodium23$2,292
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,128
Levothyroxine Sodium184$1,939
Gabapentin96$1,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$72$118,90393 claims
Lilly USA, LLCMounjaro, Trulicity$116$86,26459 claims
Boehringer IngelheimJardiance$77$41,19035 claims
AstraZenecaFarxiga$286$36,31141 claims
AbbVieLinzess, Synthroid$269$16,54934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,941 family providers in Illinois.

Other family in Alton

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →